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Polydatin ameliorates lipid and glucose 
metabolism in type 2 diabetes mellitus 
by downregulating proprotein convertase 
subtilisin/kexin type 9 (PCSK9)
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Abstract 
Background: Abnormalities in lipid and glucose metabolism are constantly observed in type 2 diabetes. However, 
these abnormalities can be ameliorated by polydatin. Considering the important role of proprotein convertase subtili-
sin/kexin type 9 (PCSK9) in metabolic diseases, we explore the possible mechanism of polydatin on lipid and glucose 
metabolism through its effects on PCSK9.
Methods: An insulin-resistant HepG2 cell model induced by palmitic acid (PA) and a db/db mice model were used to 
clarify the role of polydatin on lipid and glucose metabolism.
Results: In insulin-resistant HepG2 cells, polydatin upregulated the protein levels of LDLR and GCK but repressed 
PCSK9 protein expression, besides, polydatin also inhibited the combination between PCSK9 and LDLR. Knockdown 
and overexpression experiments indicated that polydatin regulated LDLR and GCK expressions through PCSK9. In 
the db/db mice model, we found that polydatin markedly enhanced GCK and LDLR protein levels, and inhibited 
PCSK9 expression in the liver. Molecular docking assay was further performed to analyze the possible binding mode 
between polydatin and the PCSK9 crystal structure (PDB code: 2p4e), which indicated that steady hydrogen bonds 
formed between polydatin and PCSK9.
Conclusions: Our study indicates that polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mel-
litus by downregulating PCSK9.
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Background
Lipid and glucose metabolism disorders are the main 
characteristics of insulin-resistant type 2 diabetes mel-
litus [1]; these disorders are also the basic pathology in 
diabetic microvascular complications [2]. Stable glucose-
lowering and lipid-lowering therapies effectively retard 
the progression of chronic diabetic microvascular com-
plications [3, 4]. Therefore, exploring the agents with 
both hypoglycemic and hypolipidemic effects to treat 
diabetes and its complications is necessary. Drugs that 
regulate metabolic diseases by targeting PCSK9 have 
recently drawn great attention all over the world [5–9]. 
Several studies have demonstrated that PCSK9 plays a 
vital role in the degradation of low-density lipoprotein 
receptor (LDLR) [10–13]. PCSK9 binds to LDLR and 
then, reroutes it from the endosome to the lysosome, 
where the LDLR is degraded rather than recycling back 
to the cell membrane, thereby leading to an impaired 
cholesterol uptake and elevated serum cholesterol levels 
[10–13]. Both the animal experiments and clinical studies 
have suggested that PCSK9 is also closely linked to glu-
cose metabolism [14–18] and triglyceride levels [16, 19]. 
Repressing PCSK9 expression can control serum lipids 
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and thus, ameliorate insulin resistance to some extent. As 
such, PCSK9 might be a promising target in ameliorating 
lipid and glucose metabolism disorders and improving 
insulin resistance.
Polydatin (resveratrol-3-O-β-mono-d-glucoside), also 
known as piceid, is a major active component of Polygo-
num cuspidatum Sieb. et Zucc. It is a glycoside of resvera-
trol. Previous studies have shown that polydatin exerts 
several pharmacological effects, including anti-inflam-
mation [20–23], anti-oxidant [24, 25], anti-allergy [26], 
anti-cancer [27], lipid-lowering [28, 29], and cardiovascu-
lar- protection effects [30, 31]. We found that polydatin 
could improve lipid and glucose metabolism in STZ-
induced diabetic rats and regulate GCK and LDLR expres-
sion [32]. Considering the close relationship between 
PCSK9 and LDLR, as well as insulin resistance, we sought 
to determine whether polydatin works by affecting PCSK9.
Based on the above background, we chose an insulin-
resistant HepG2 cell model induced by PA [32] and a db/
db mice model to explore the exact effects of polydatin on 
PCSK9, LDLR, GCK, and other metabolic parameters. To 
further elucidate its interaction with PCSK9, polydatin was 
docked into the active pocket of the PCSK9 crystal struc-
ture using Surflex-Dock in Sybyl 7.3.5 to analyze the specific 
binding motifs between polydatin and PCSK9. Our results 
demonstrate that polydatin ameliorates lipid and glucose 
metabolism in type 2 diabetes mellitus by downregulating 
proprotein convertase subtilisin/kexin type 9 (PCSK9).
Methods
MTT cell proliferation assay
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetra-
zolium bro-mide (MTT, Sigma, USA) assay was used to 
detect cell viability of HepG2 cells for increasing con-
centrations of polydatin under insulin resistant condi-
tion induced by PA. Briefly, cells were seeded in 96-well 
plate, and incubated with 0.25  μM PA for 24  h with or 
without polydatin after cell subconfluence. Then 20 μl of 
MTT (0.5 mg/ml) was added to each well and incubation 
continued at 37 °C for an additional 4 h. The medium was 
then carefully removed, so as not to disturb the formazan 
crystals formed. Dimethyl sulphoxide (DMSO, 200  μl, 
Sigma, USA), which solubilizes the formazan crystals, 
was added to each well and the absorbance of solubilized 
blue formazan was read at wave-length of 570 nm using a 
microplate reader (Bio-Tek, USA). The reduction in opti-
cal density caused by polydatin used as a measurement of 
cell proliferation, normalized to cells incubated in control 
medium, which were considered 100 % viable.
Insulin resistant cell model and the treatment of polydatin
HepG2 cells (American Type Culture Collection, Rock-
ville, MD,USA) were grown at 37  °C in high-glucose 
DMEM (Gbico, Invitrogen, USA) containing: 10 % (v/v) 
FBS (Gibco, Invitrogen, USA), 100  U  mL−1 penicil-
lin, 100 mg mL−1 streptomycin (Hyclone, USA) and 1 % 
l-glutamine (Sigma, USA). Cells were grown in a humidi-
fied atmosphere of 95 % air/5 % CO2 at 37 °C, and in six 
multi-well plates at proper cell densities. At appropriate 
subconfluence, the HepG2 cells were serum-starved for 
12 h and then divided into different groups for different 
treatments. Cells were preincubated with the presence 
or absence of polydatin (Chuangwei, Beijing, China) 
at the dosage of 5, 10, 20, and 40 μM for 1  h, and then 
stimulated with or without 0.25 mM of PA (Sigma, USA), 
which was prepared as previous study [33] for another 
24 h. Considering that PA was dissolved in BSA (low free 
fatty acid, MP Biomedical, USA), 0.5  % BSA was added 
as normal control. All experiments were performed in 
triplicate.
Animal model
Twenty-one healthy specific pathogen free female db/db 
leptin receptor deficient type 2 diabetic mice (abbrevi-
ated by db/db) aged 6 weeks and seven female wild type 
C57BL/6 mice (abbreviated by C57) aged 6  weeks were 
supplied by the Experimental Animal Center of Sun Yat-
sen University (Guangzhou, China; animal quality certi-
fication number: 201403212). The mice were adapted to 
the environment for 1 week and then randomly divided 
into 4 groups based on the weight and fasting blood glu-
cose (FBG) levels as follows: C57 control group (n = 7), 
db/db model group (n =  7), polydatin treatment group 
(n  =  7, 100  mg/kg, dissolved in 0.5  % (w/v) CMC-Na; 
purity >98 %, HPLC; Zelang, Nanjing, China), and piogl-
itazone treatment group (n =  7, 10  mg/kg, dissolved in 
0.5  % (w/v) CMC-Na; Takeda, Japan, subpackaged by 
Tianjin Takeda). The mice were administered by gavage 
6 days every week at 9:30–10:30 am, totally for 4 weeks. 
We weighed the mice every day to determine the exact 
dose of drugs needed to be given and measured the FBG 
levels every other week using a One-Touch glucometer 
(Johnson and Johnson, USA) after starvation for 12  h. 
The animals were housed in a temperature-controlled 
(20–25  °C) and humidity-controlled (40–70  %) barrier 
system with 12:12 h light and dark cycle.
Plasma and liver tissue collection
At the end of the experiment, all animals were fasted for 
12  h and blood sample was collected by drainage from 
the retroorbital venous plexus after the FBG detection. 
Serum was obtained by centrifuge at 3000g for 15  min 
and stored at −80 °C to detect the metabolic parameters. 
Liver samples were quickly weighed and excised into 
same parts, and a small part was fixed in 10  % neutral 
buffered formalin and subsequently embedded in paraffin 
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or for further Oil Red O staining, and the left was frozen 
in liquid nitrogen immediately and stored at −80  °C for 
other assays.
Lipid profile and PCSK9 level in serum
The serum was balanced at room temperature for 30 min 
and diluted with NaCl solution (0.9 %) by 1:1. Then the 
total cholesterol (TC), triglyceride (TG), lower density 
lipoprotein cholesterol (LDL-C), and high density lipo-
protein cholesterol (HDL-C) levels were detected using 
the auto-analysis biochemical instrument (Beckman 
coulte CX5). Serum PCSK9 level was detected following 
the instruction of the Human PCSK9 ELISA Kit (CUSA-
BIO; Wuhan, China).
The content of TC, TG, and glycogen in liver
The frozen liver tissues were rinsed, dried, and weighed 
for hepatic TC, TG, and glycogen measurement accord-
ing to the manufacturer’s instructions (Jiancheng; Nan-
jing, China). Briefly, 100  mg liver samples were added 
to 0.2  ml 0.9  % NaCl buffer and homogenized by using 
a homogenizer on ice, followed by the extraction step 
with a solvent having a 2:1 (v/v) chloroform-to- metha-
nol ratio at room temperature. After mingled thoroughly, 
the samples were stewing for 18 h at room temperature 
and then the samples were separated into three parts: 
water phase (the upper layer), tissue fragment (the mid-
dle layer), lipid phase (the lowest layer). The lipid phase 
was collected carefully to detect the TC and TG levels in 
liver. The glycogen was hydrolyzed in base solutions for 
20  min in boiling water and then diluted the sample to 
1 % solution to detect the glycogen content.
H&E staining
Ten percent neutral formalin-fixed paraffin-embedded 
liver sections (3–4  μm) were stained with hematoxylin 
and eosin (H&E) using standard protocols. Briefly, the 
sections were deparaffinization, rehydrated, stained with 
hematoxylin and agitation for 30 s, stained the slide with 
1  % eosin solution for 20  s after being washed in H2O, 
dehydrated the sections and covered with neutral balsam.
Oil Red O staining
The livers were fixed for over 24  h, dehydrated in 15 and 
30  % sucrose solutions at −4  °C in succession, OCT- 
embedded, cold-sliced (8–10 μm), and refixed at room tem-
perature for another 15 min, Oil Red O stained for 15 min, 
differentiated with 75 % alcohol, counterstained with hema-
toxylin for 2 min, and finally covered with neutral balsam.
Western blot assay
Firstly, the lysis buffer was prepared by adding protease 
and phosphatase inhibitor cocktail (100×; Thermo, USA) 
to RIPA lysis buffer (pH 8.0, 50 mM Tris, 150 mM NaCl, 
0.02 % sodium azide, 0.1 % SDS, 1 % NP-40, 0.5 % sodium 
deoxycholate, 1 mM EDTA, and so on). For the cells, the 
plate was rinsed with ice-cold PBS buffer for three times 
and then collected the cells with the lysates. For the liver 
tissues, samples were added to cold lysis buffer and homog-
enized by using a homogenizer. The lysates or homogenates 
were centrifuged and then, the supernatant was collected. 
Equal amounts of protein samples were separated by 8 % 
(v/v) SDS-PAGE and electrophoretically transferred onto 
a nitrocellulose membrane. After blocking with 5  % non-
fat milk at room temperature for 1.5  h, the membranes 
were incubated with the corresponding primary anti-
LDLR (1:1000; Santa Cruz, CA, USA), anti-GCK (1:1000; 
Santa Cruz, CA, USA), anti-PCSK9 (1:500; Santa Cruz, 
CA, USA), and anti-Tubulin (1:10,000; Sigma, USA) anti-
bodies at 4 °C overnight. The membranes were then incu-
bated with horse radish peroxidase-conjugated secondary 
antibodies (anti-rabbit IgG or anti-mouse IgG, 1:10,000; 
Promega, USA) for 1.5  h at room temperature, and the 
immunoreactive protein bands were visualized using 
enhanced chemiluminescence reagents (Thermo Fisher 
Scientific; Rockford, IL, USA) with a GE ImageQuant LAS 
4000 mini (GE healthcare; Waukesha, WI, USA). The inten-
sity of protein bands was quantitated using a Image J analy-
sis software (Version 1.46r, Scion, Frederick; MD, USA).
Quantitative real‑time PCR
Quantitative real-time PCR, which was performed with 
some modifications as described previously [34], was 
used to determine the relative mRNA expression levels. 
Briefly, total RNAs were prepared using RNAiso plus 
(Takara, Japan). The cDNA from the total RNA was syn-
thesized with a PrimeScript™ RT Reagent Kit (Takara, 
Japan). PCR amplification for each gene was performed 
using SYBR® Green (Toyobo, Japan) according to the 
manufacturer’s protocol, and the results were normal-
ized to β-actin expression. The primers were synthesized 
by Invitrogen (Shanghai, China) as described in previ-
ous study [35]. Mouse LDLR primers (Forward: ACCTG 
CCGACCTGATGAATTC, Reverse: GCAGTCATGTT 
CACGGTCACA); Mouse PCSK9 primers (Forward: TT 
GCAGCAGCTGGGAACTT, Reverse: CCGACTGTGAT 
GACCTCTGGA). Mouse β-actin primers (Forward: 
TGCGTGACATCAAAGAGAAG, Reverse: GATGCCA 
CAGGATTCCATA).
Immunohistochemistry and double immunofluorescence 
staining
Sections of liver (4 μm thick) were processed using a stand-
ard immunostaining protocol. Briefly, after deparaffiniza-
tion, hydration and blockage of endogenous peroxidase 
routinely, sections were pretreated by microwave for 20 min 
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in EDTA recovery buffer for antigen retrieval, followed by 
incubation sequentially with blocking agent, rabbit polyco-
lonia PCSK9 antibody (1:100; Santa Cruz, CA, USA) and 
mouse monocolonia LDLR antibody (1:100; Santa Cruz, 
CA, USA) and corresponding secondary antibody (1:200; 
KPL, USA). Slides were counterstained with hematoxy-
lin (Google Biotech, Wuhan, China) after 3 min of diam-
inobenzidine (DAKO, CA, USA) reaction, and covered 
slices using neutral balsam (Sinopharm Chemical Reagent 
Co., Ltd, Shanghai, China), then photographed and con-
verted to a digital image using light microscopy equipped 
with camera (NIKON DS-U3/LSM700; CARL ZEISS). 
Negative control was carried out by omitting the primary 
antibody and revealed no labeling (data not shown). The 
double immunofluorescence staining was similar with the 
above steps except that both the LDLR and PCSK9 primary 
antibody (1:100/1:100) were co-incubated in the same slide, 
followed by fluorenscence-conjuated secondary antibod-
ies (1:400/1:300, respectively) and DAPI (Google Biotech, 
Wuhan, China) staining in nuclear in dark.
Co‑immunoprecipitation (Co‑IP)
20  μl of protein agarose A/G beads (calbiochemR, USA) 
was added into 300 μg of protein lysates for pre-clearance 
of non-specific interaction. The supernatant was mixed in 
1 μg of PCSK9 antibody (5 μl) and incubated at 4 °C over-
night. The next day, 20 μl of protein agarose A/G beads was 
added and incubated at 4 °C for another 2 h. After centri-
fuging at 4 °C, 12,000g for 30 s, the supernatant was care-
fully divided without touching the beads. Rinsed the beads 
with indicated washing buffer for 3 times and mingled 
with the loading buffer finally to perform the western blot 
and proteins were pulled down using their specific anti-
bodies. Rabbit IgG (Beyotime Biotech, Shanhai, China).
PCSK9 small interfering RNA (siRNA) assay
Three pairs of specific siRNA targeting PCSK9 were 
designed and synthesized by GenePharma (Shanghai, 
China). Through western blot assay, we screened out 
the siRNA numbered 1153 with the best interfering 
effect. The sequences of siRNA-1153 used in the sequent 
experiment were as following: sence: 5′-CCCUCAUAGG 
CCU GGAGUUTT-3′; antisence: 5′-AACUCCAGGCCU 
AUGAGGGTT-3′. 5  μl of siRNA-1153 and 5  μl of 
RNAiMAX (Invitrogen, Shanhai, China) were diluted in 
150 μl of opti-MEM (Invitrogen, Shanhai, China), respec-
tively, and then mingled together for a 5-min incubation. 
Thereafter the mixed reagent was added into the HepG2 
cells for 24 h.
PCSK9 wild type plasmid overexpression
HepG2 cells were plated in six-well dishes and were 
infected with empty vector (pENTER) and PCSK9 wild 
type plasmid (Vigene, Shandong, China), respectively, at 
a multiplicity of Lipofectamine® LTX and Plus (Invitro-
gen, Shanhai, China) in opti-MEM (Invitrogen, Shanhai, 
China) for 24 h.
Molecular docking
Surflex-Dock in Sybyl 7.3.5 (Tripos, Inc., St. Louis, MO, 
USA) that was applied to study molecular docking uses 
a potent search engine to dock ligands into a protein’s 
binding site [36]. Polydatin was docked into the active 
pocket of PCSK9 crystal structure using Surflex-Dock 
to analyze the specific motifs between polydatin and 
PCSK9. The PCSK9 crystal structure was obtained from 
PDB (PDB code: 2p4e).
Results
Polydatin up‑regulated the protein expressions of LDLR 
and GCK but down‑regulated PCSK9 level in PA‑induced 
insulin‑resistant HepG2 cells
In insulin-resistant HepG2 cells, polydatin showed no 
cytotoxicity below 80  μM for 24  h in the MTT assay 
(Fig.  1a), the protein expressions of LDLR and GCK 
(Fig.  1b, c) were downregulated, which were obvious at 
the concentration of 20 μM for 24 h (P < 0.01). We then 
detected the protein expression of PCSK9, a protein that 
binds to LDLR and induces its degradation, and found 
that PCSK9 level was increased under the insulin-resist-
ant conditions, which could be reversed by polydatin 
treatment (Fig. 1d) as expected (P < 0.001). Therefore an 
assumption that polydatin regulates LDLR and GCK lev-
els through down-regulating PCSK9 arouses our interest.
Polydatin regulated LDLR and GCK through PCSK9
As mentioned above that PCSK9 binds to LDLR, the Co-IP 
assay showed that PCSK9 interacted with LDLR in control 
cells, which was augmented in the insulin-resistant HepG2 
cells (Fig. 2a). Polydatin treatment obviously inhibited the 
combination between PCSK9 and LDLR (Fig. 2a). To fur-
ther explore the possible effects of PCSK9 on LDLR and 
GCK, we carried out a series of experiments using PCSK9 
siRNA and overexpressing plasmids.
We first detected the silencing efficiency of PCSK9-
siRNA. The protein levels of PCSK9 were efficiently 
depleted by 60  % after PCSK9-siRNA 1153 treatment 
as confirmed by western blot assay (Fig.  2b). Concomi-
tant with decreased PCSK9 levels, siRNA-1153 could 
increase the expression of LDLR under the PA treatment 
conditions compared with the control group (Fig.  2c). 
However, the GCK level was not affected by siRNA-
1153 (Fig. 2d). Interestingly, after PCSK9 was interfered 
by siRNA, the upregulated effects of LDLR and GCK 
induced by polydatin under insulin-resistant conditions 
disappeared (Fig. 2c, d).
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Fig. 1 In PA-induced insulin resistance model, the expression of PCSK9, LDLR, and GCK after polydatin treatment. a Insulin resistant HepG2 cells 
were incubated with polydatin of the indicated concentrations for 24 h and measured by MTT assay. b LDLR and GCK protein expression with poly-
dation treatments in 5, 10, 20, 40 μM for 24 h. c LDLR and GCK protein expression with polydation treatments in 20 μM for different time. d PCSK9, 
LDLR, and GCK expression with polydatin treatment in 20 μM for 24 h. All experiments were performed with polydatin (indicated concentration) 
pretreatment for 2 h, and then incubated with 0.25 mM of PA for another 24 h to induce insulin resistance for more than three times. Intensities 
were quantified and normalized against the level of α-tubulin abundance in corresponding BSA-treated cells. $p < 0.05 vs. Con; *p < 0.05, **p < 0.01, 
and ***p < 0.001 vs. LDLR levels in the control group (Con); ^p < 0.05 and ^^p < 0.01 vs. GCK levels in the control group (Con); ###p < 0.001 vs. IR 
group
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Fig. 2 Polydatin regulated LDLR and GCK expression possibly through PCSK9. a Co-IP assay was performed to explore whether polydatin affected 
the combination of PCSK9 and LDLR according to the “Methods” above. b The interfering efficiency of PCSK9 by siRNA was screened, and the 
second sequence si1153 was chosen for subsequent experiments and the negative sequences were used as control. c, d LDLR and GCK expression 
under PCSK9 knockdown conditions. e, f LDLR and GCK expression under PCSK9 overexpression conditions. Overexpression of PCSK9 with Human 
wild-type PCSK9 plasmids and the vector PENTER plasmid were used as control. SiRNA and overexpression experiments were all divided into three 
groups: Control group, IR group, and IR + polydatin group. The first three lanes were treated with the negative SiRNA squences or pENTER vector as 
control and the last three lanes were treated with siRNA-1153 sequences or Human wild-type PCSK9 plasmids, respectively. ###p < 0.001 vs. control 
group (Con); *p < 0.05, **p < 0.01 and ***p < 0.001 vs. LDLR levels in the control group (Con); ^^p < 0.01 and ^^^p < 0.001 vs. PCSK9 levels in the 
control group (Con)
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Overexpression of the PCSK9 wild-type plasmid 
caused a sharp decline in LDLR and GCK expressions 
in the insulin-resistant group; these decreases, how-
ever, were restored by polydatin to nearly control levels 
(Fig. 2e, f ).
Accordingly, polydatin upregulated the protein 
expressions of LDLR and GCK possibly through the 
inhibition of PCSK9 in PA induced insulin resistant 
HepG2 cells.
Polydatin ameliorated lipid and glucose disorders 
and protected the liver in db/db mice
In order to confirm the effects of polydatin on lipid 
and glucose metabolism, we testified it in the db/db 
mice model. Polydatin attenuated FBG whose changes 
observed were slightly better than that in the pigolitazone 
treatment group (Fig. 3a) and decreased total cholesterol 
(TC), triglyceride (TG), and low-density lipoprotein cho-
lesterol (LDL-C) levels (Table 1). Furthermore, polydatin 
Fig. 3 Polydatin ameliorated lipid and glucose metabolism and protected the liver from steatosis in db/db mice. a Fasting blood glucose levels 
(FBG) were measured every other week. b–d In the liver (n = 6), glycogen, TC and TG levels were determinated as described in “Methods”. e 
Histochemical analysis of fresh liver tissue was performed by staining with H&E or Oil Red O (×400 magnification). ***p < 0.001 vs. C57; #p < 0.05, 
##p < 0.01 and ###p < 0.001 vs. db/db, cv center vain
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significantly increased glycogen contents (Fig.  3b) and 
decreased TC and TG accumulation in the liver (Fig. 3c, 
d). H&E and Oil Red O staining both showed obvious 
liver pathological injury accompanied by the accumula-
tion of fat and large distended lipid droplets in the liver 
of db/db mice compared with the C57 mice, which was 
remarkably reduced after polydatin treatment for 4 weeks 
(Fig. 3e).
Polydatin significantly decreased PCSK9 mRNA lev-
els (Fig.  4a) but had no effect on LDLR mRNA levels 
(Fig. 4b). Polydatin markedly inhibited PCSK9 expression 
(Fig. 4c) and increased protein levels of LDLR and GCK 
in db/db mice (Fig.  4d, e). ELISA assay was performed 
to measure the serum PCSK9 levels under polydatin-
treatment conditions. As shown by Fig. 4f, there was no 
significant change in PCSK9 among the three groups. 
Immunohistochemistry staining showed that polydatin 
improved LDLR expression accompanied by the decrease 
in PCSK9 level (Fig. 5a) and immunofluorescence stain-
ing revealed the co-location of LDLR and PCSK9 in the 
liver to some extent (Fig. 5b), which was consistent with 
the western blot results.
Our vivo study better elucidated that polydatin could 
improve the lipid and glucose metabolism in db/db mice 
model possibly by inhibiting PCSK9.
Molecular docking
To better figure out its interaction with PCSK9, poly-
datin was docked into the active pocket using Sur-
flex-Dock in Sybyl 7.3.5. The molecular docking assay 
indicated that polydatin (Fig. 6a) could bind to the active 
pocket of the PCSK9 crystal structure (PDB code: 2p4e) 
(Fig. 6b) and formed steady hydrogen bonds with PCSK9 
in several amino residues, including Cys358, Val 435, 
Asn439, and Asp651 (Fig.  6c). The interaction between 
PCSK9 and polydatin might inhibit the combination 
between PCSK9 and LDLR, and then decreased the deg-
radation of LDLR.
Discussion
The current study was undertaken to explore the effect 
and molecular mechanism of polydatin on lipid and glu-
cose metabolism in type 2 diabetes. Polydatin, also known 
as piceid, is a main glucoside of resveratrol whose gluco-
side group bonded in the C-3 position substitutes with a 
hydroxyl group [20]. Both resveratrol and polydatin have 
the effects of anti-inflammation, anti-oxidation, cytopro-
tection in stress conditions, anti-hyperlipidemia, anti-
hyperglycemia and many other cardiovascular protection 
merits [29, 32, 37–40], mainly through the signal path-
ways such as IKKs/NF-κB, Nrf2/ARE, Akt, AMPK, AMPK 
-Kir6.2/K-ATP [25, 32, 40–42]. The molecular mecha-
nisms reported before are so widespread in almost all 
diseases that more immediate targets of polydatin should 
be explored to better explain the mode of drug action. 
According to our previous study, we found LDLR and 
GCK were significantly increased by polydatin in Strep-
tozocin induced diabetic rats [32]. As reported, LDLR is 
the main receptor inducing cholesterol (especially LDL-
C) clearance in circulation and consequently balances 
serum lipid level [43]. GCK can catalyze the phospho-
rylation of glucose to glucose 6-phosphate (G6P) as a key 
step of glycolysis, glycogen synthesis, and the pentose 
phosphate pathway [44]. And the expression of GCK is 
sharply decreased in diabetic mice [45]. Our data indeed 
indicated that polydatin can upregulate the expressions 
of LDLR and GCK both in  vivo and vitro experiments, 
thereby improving the lipid and glucose metabolism.
While how polydatin regulates the expression of LDLR 
and GCK is unclear. Several studies have indicated that 
PCSK9 can bind to and induce the degradation of LDLR 
through both intracellular and extracellular pathways 
[46]. On the one hand, the PCSK9-LDLR complex is 
formed in the endoplasmic reticulum and then trans-
fers directly from the Golgi network to the lysosome 
[47]. On the other hand, the secreted PCSK9 binds to 
LDLR on the cell surface, followed by internalization and 
Table 1 Polydatin attenuated serum lipid levels of db/db mice after 4 weeks of polydatin treatment (n = 6–7)
Datas are represented as mean ± SD
Serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) of db/db mice were measured after 4 weeks of 
polydatin treatment (n = 6–7)
a P < 0.05 vs. C57
bb P < 0.01
bbb P < 0.001 vs. db/db
Group Dose (mg/kg) TC (mmol L−1) TG (mmol L−1) LDL‑C (mmol L−1) HDL‑C (mmol L−1)
C57 2.18 ± 0.16 1.76 ± 0.26 0.49 ± 0.04 1.05 ± 0.08
db/db 4.06 ± 0.27bbb 2.87 ± 0.89 0.64 ± 0.08bb 1.97 ± 0.23bbb
Polydatin 100 3.24 ± 0.56abb 1.65 ± 0.61a 0.56 ± 0.06a 1.62 ± 0.31abb
Pioglitazone 10 3.89 ± 0.61 1.41 ± 0.23 0.70 ± 0.17 2.07 ± 0.32
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degradation of LDLR in lysosomes [6, 13, 48, 49]. There-
fore, PCSK9 arouses our interest and we make a reason-
able speculation that polydatin might increase LDLR 
expression through decreasing PCSK9 levels. This will 
improve lipid metablism as well as insulin resistance, 
which will upregulate GCK levels and ameliorate hyper-
glycemia in a reciprocal way. Both vitro and vivo experi-
ments are designed to demonstrate our inference.
In vitro, we firstly detected the levels of PCSK9, LDLR, 
and GCK using an insulin-resistant cell model induced 
Fig. 4 Polydatin inhibited PCSK9 level and upregulated the protein levels of LDLR and GCK. a, b PCSK9 mRNA and LDLR mRNA levels were 
detected by quantitative real-time PCR assay. c–e Protein levels of PCSK9, LDLR, and GCK were detected by Western blot analysis in mouse liver 
as described in “Methods”. Relative fold increases of each protein are shown (mean ± SD, n = 6). f ELISA assay was performed to detect the serum 
PCSK9 levels according to the manufacture’s instruction. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. db/db
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Fig. 5 The relationship of LDLR and PCSK9 expression in the liver. a Immunohistochemistry results of LDLR and PCSK9 in the liver. For each repre-
sentative section, the cells were considered to be positive for LDLR and PCSK9 if the cell bodies were stained brown and the relative contents were 
calculated by Image J analysis software. b Immunofluorescence staining revealed the relative expression and co-location of LDLR and PCSK9 in the 
liver. Six liver samples were used per group. (×400 magnification)
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by PA [32, 33]. As expected, we discovered an increase 
in PCSK9 expression in PA-induced insulin-resistant 
HepG2 cells that was reversed to control levels by poly-
datin, which was similar to the findings published in 
a previous study [50]. Further co-IP assay revealed 
decreases in LDLR (160  KD) content pulled down 
by PCSK9. These results indicate that polydatin may 
increase LDLR levels by repressing PCSK9 expression 
together with inhibiting the combination of PCSK9 and 
LDLR. SiRNA assay was performed to verify the above 
hypothesis. The upregulating effects of polydatin on 
LDLR and GCK were disappeared in the PA  +  PCSK9 
knockdown group. Conversely, overexpression of PCSK9 
wild-type plasmids caused a sharp decrease in LDLR and 
GCK levels compared with those in the empty vector 
group in insulin-resistant HepG2 cells. And restoration 
to control levels was achieved by polydatin. These results 
demonstrate that polydatin is involved in the regulation 
of LDLR and GCK by affecting PCSK9.
To better manifest our viewpoint, we further used a 
db/db mice model, which was mainly characterized by 
obesity, hyperglycemia, dyslipidemia, and insulin resist-
ance [51, 52]. As expected, the polydatin treatment group 
showed significant hypoglycemia and lipid-lowering 
effects, consistent with a previous study [28]. PCSK9 
mRNA and protein levels were enhanced in the liver tis-
sues of db/db model. By comparison, LDLR did not show 
any change at the mRNA level, but exhibited a decrease 
in LDLR transcription in db/db mice, consistent with 
the InsR−/− mice [18]. LDLR and GCK levels were both 
upregulated while the PCSK9 mRNA and protein levels 
were suppressed in db/db mice after polydatin treatment, 
corresponding to the vitro study. Immunohistochemistry 
and double immunofluorescence staining demonstrated 
the same results, and indicated the co-location of LDLR 
with PCSK9 on the cell surface to some extent, consist-
ent with a previous study [47]. Many studies indicate that 
the function of PCSK9 as a secreted factor is physiologi-
cally significant [13, 16], thus we explored whether serum 
PCSK9 levels were affected by polydatin. We detected 
serum PCSK9 by ELISA and found no obvious change 
in the db/db mice group compared with that of the C57 
group; such a result corresponds to previous reports [17, 
53]. Different from statins’ upregulated effect of serum 
PCSK9 level [54], polydatin showed no significant influ-
ence on serum PCSK9 level. Our results imply that poly-
datin may enhance hepatic LDLR levels by decreasing 
PCSK9 contents and inhibit the PCSK9-LDLR complex 
formed directly in the liver rather than an extracellular 
route.
Both in  vitro and in  vivo studies revealed that poly-
datin ameliorates lipid and glucose metabolism disorders 
in a manner that is closely linked to PCSK9. However, 
the mechanism underlying the influence of polydatin on 
PCSK9 remains unknown. Hence, a molecular docking 
assay was performed, and several hydrogen bonds were 
observed to be formed between polydatin and the active 
pocket of the PCSK9 crystal structure. These results indi-
cate that polydatin may bind to PCSK9 and change the 
conformation of PCSK9, thereby blocking the interaction 
between PCSK9 and LDLR and the degradation of LDLR. 
The results of this work provide a suitable theoretical 
basis for polydatin in lipid and glucose metabolism regu-
lation by interfering with PCSK9.
Fig. 6 Molecular docking revealed a direct combination between 
polydatin and PCSK9 crystal structure (PDB code: 2p4e). a The chemi-
cal structure of polydatin, which contained several phenolic hydroxyl 
groups. b Docking pose of polydatin in the active pocket of the 
PCSK9 crystal structure. c Polydatin formed steady hydrogen bonds 
with PCSK9 in several amino residues consisting of Cys358, Val435, 
Asn439, and Asp651. Key residues are shown in stick representation. 
Carbon, oxygen, and hydrogen for the polydatin are colored yellow, 
red, and silver, respectively
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Conclusions
Polydatin ameliorates lipid and glucose metabolism via 
a mechanism that is closely relevant to its binding and 
blocking effect on PCSK9. Our study provides a new 
basis for further exploration of the therapeutic potentials 
of polydatin in the intervention and prevention of insulin 
resistance and regulation of lipid and glucose metabolism 
for future clinical use.
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